TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37044364
Drug: Multifaceted strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted strategy with a multidisciplinary approach including telehealth tools, continued education, pharmacological and non-pharmacological treatment, and behavioral change.
Study: 37045500
Drug: Abbreviated antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated antiplatelet therapy (APT)
Study: 37045500
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet therapy (APT)
Study: 37045504
Drug: CYP2C19 genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 genotyping with clopidogrel-based therapy (RMs or NMs)
Study: 37045504
Drug: CYP2C19 genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 genotyping with clopidogrel-based therapy (IMs or PMs)
Study: 37045565
Drug: Dopamine or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine or Epinephrine administration
Study: 37045569
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (1.6%) + chondroitin sulfate (2%) therapy (Ialuril)
Study: 37045708
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (LDN) 4.5 mg for 8 weeks
Study: 37046094
Drug: Antibodies against
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies against endogenous retroviruses
Study: 37046122
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g per day I + AX for 21 days
Study: 37046290
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy (CBT) for tinnitus
Study: 37046681
Drug: Fluvastatin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (6 mg/kg/day) with Celecoxib (fixed daily dose)
Study: 37048135
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of copeptin and hs-cTnT
Study: 37049576
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement (probiotics, prebiotics, vitamin D, zinc, and selenium)
Study: 37050861
Drug: Venglustat administered
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venglustat administered as food admixture
Study: 37050937
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Global Registry of Acute Coronary Events (GRACE) score with ceramides
Study: 37051014
Drug: Participants' estimates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants' estimates of others' cannabis use (weekly or more often)
Study: 37051129
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) from postoperative day 1 to day 5 plus oral food 'at will' (treatment arm)
Study: 37051129
Drug: Oral food
Normalized name: Nutritional Supplement Oral Food, Solid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral food 'at will' alone (control arm)
Study: 37051756
Drug: Venetoclax 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 600 mg daily with azacitidine during induction cycles; maintenance arms included azacitidine with 400 mg venetoclax or 400 mg venetoclax alone.
Study: 37051756
Drug: MRD guidance
Normalized name: ZINC OXIDE 120 mg in 1 mL TOPICAL CREAM [GUIDANCE TO GLOW TRU SPF 35]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRD guidance for azacitidine discontinuation
Study: 37051756
Drug: Venetoclax doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax doses >400 mg with azacitidine
Study: 37051821
Drug: Glenohumeral joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glenohumeral joint corticosteroid injection
Study: 37053246
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral accelerated theta burst stimulation (aTBS) administered as 3 sessions daily for 10 days, with 1,800 pulses delivered continuously to the right DLPFC and intermittently to the left DLPFC.
Study: 37053246
Drug: Sham TBS
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TBS treatment administered as 3 sessions daily for 10 days.
Study: 38758212
Drug: Automated Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Insulin Delivery
Study: 37053529
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard insulin delivery)
Study: 37054503
Drug: Tyrosine receptor
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine receptor kinase inhibitor (TRKi) treatment in patients with simple genomics NMT.
Study: 37054503
Drug: First-generation TRKi
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation TRKi treatment in patients with complex genomics NMT.
Study: 37054556
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus platinum chemotherapy (GC) + bevacizumab
Study: 37054556
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus platinum chemotherapy (GC)
Study: 37054888
Drug: β-glucan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-glucan 1.5 g
Study: 37054888
Drug: β-glucan 3
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-glucan 3 g
Study: 37054888
Drug: β-glucan 6
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-glucan 6 g
Study: 37055198
Drug: 6 L NC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 L NC 100% oxygen
Study: 37055205
Drug: SIESTA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIESTA in combination with treatment as usual (TAU) for ADHD
Study: 37055207
Drug: SOC+L (Leflunomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC+L (Leflunomide 100 mg/day for 3 days followed by 10-20 mg/day for 7 days)
Study: 37055207
Drug: SOC+L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC+L
Study: 37055279
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 6 cycles of gemcitabine
Study: 37055279
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 3 cycles of gemcitabine followed by chemoradiation therapy (CRT) and another 3 cycles of gemcitabine
Study: 37055640
Drug: Circulating tumour
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating tumour DNA (ctDNA) detection and profiling after curative intent therapy
Study: 37055702
Drug: Air-Q Blocker
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-Q Blocker
Study: 37056765
Drug: Radiotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy of 24 Gy/3 fractions/3-10 days plus liposomal irinotecan (80mg/m) followed by camrelizumab and anti-angiogenic treatment
Study: 37057394
Drug: Anti-TG2 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TG2 antibodies
Study: 37058479
Drug: Vaccination (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination (2 doses)
Study: 37058726
Drug: Any opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any opioid administration
Study: 37058726
Drug: Lowest opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest opioid dose group
Study: 37058726
Drug: Third opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third opioid dose group
Study: 37059327
Drug: S201086/GLPG1972 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: S201086/GLPG1972 75 mg
Study: 37059327
Drug: S201086/GLPG1972 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: S201086/GLPG1972 150 mg
Study: 37059327
Drug: S201086/GLPG1972 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: S201086/GLPG1972 300 mg
Study: 37060053
Drug: Pragmatic digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic digital health obesity treatment intervention
Study: 37060055
Drug: AGuIX nanoparticles
Normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AGuIX nanoparticles (50, 75, and 100 mg/kg) added to standard concomitant radio-chemotherapy (temozolomide and radiotherapy)
Study: 37060236
Drug: Fixed Starting
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Starting Dose (FSD) of niraparib, 300 mg once daily
Study: 37060236
Drug: Individualized Starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individualized Starting Dose (ISD) of niraparib, 200 mg once daily for patients with baseline body weight < 77 kg or baseline platelet count < 150,000/µL; 300 mg once daily for all other patients
Study: 37060236
Drug: Individualized Starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individualized Starting Dose (ISD) of niraparib
Study: 37060236
Drug: Fixed Starting
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Starting Dose (FSD) of niraparib
Study: 37060420
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy - three sessions each week for 12 weeks
Study: 37060432
Drug: Relugolix in
Normalized name: Product containing relugolix in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix in combination with abiraterone
Study: 37060432
Drug: Relugolix in
Normalized name: Product containing relugolix in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix in combination with apalutamide
Study: 37060458
Drug: Dersimelagon (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dersimelagon (oral selective MC1R agonist)
Study: 37060545
Drug: High-dose VE303
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose VE303 (8.0 × 10^9 CFUs)
Study: 37060545
Drug: Low-dose VE303
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose VE303 (1.6 × 10^9 CFUs)
Study: 37060917
Drug: ChAdOx1 RVF
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 RVF vaccine (5 × 10^10 viral particles)
Study: 37061109
Drug: Cenicriviroc (CVC)
Normalized name: salicylic acid
DrugBank: Cenicriviroc (DB11758)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc (CVC) 150 mg once daily for 12 months
Study: 37061169
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CADe (GI-Genius; Medtronic) and Endocuff Vision (ECV; Olympus)
Study: 37061234
Drug: ETN monotherapy
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN monotherapy
Study: 37060915
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once daily for 5 days)
Study: 37060915
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (including low-dose corticosteroids 6 mg once daily for 10 days)
Study: 37060915
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose corticosteroids
Study: 37061361
Drug: Supervised high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised high-intensity interval training during neoadjuvant chemoradiation therapy
Study: 37061361
Drug: Unsupervised moderate-to-vigorous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised moderate-to-vigorous exercise after therapy
Study: 37061619
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg IV, Q3weeks × 4) and nab-paclitaxel (100 mg/m2)
Study: 37061715
Drug: Comprehensive supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive supervised exercise program (CSEP) consisting of a 12-week intensive phase with 3 exercise sessions of 1 hour per week, followed by a maintenance phase with home exercises and monthly tele-consultations with a physiotherapist.
Study: 37061794
Drug: $500 monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: $500 monthly stipend
Study: 37061810
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 10 or 30 µg daily
Study: 37062298
Drug: Ritlecitinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 200 mg + 50 mg
Study: 37062298
Drug: Ritlecitinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 200 mg + 30 mg
Study: 39445776
Drug: Ritlecitinib 50
Normalized name: ritlecitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 50 mg
Study: 37062422
Drug: TG103 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 3 mg
Study: 37062422
Drug: TG103 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 7.5 mg
Study: 37062422
Drug: TG103 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 15 mg
Study: 37062422
Drug: TG103 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG103 22.5 mg
Study: 37062500
Drug: First-line anti-TNF
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line anti-TNF therapy
Study: 37062579
Drug: Caregiver's gender,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver's gender, biological relatedness, household composition, and family cohesion
Study: 37062658
Drug: Dual immuno-oncology
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual immuno-oncology agents (IO+IO)
Study: 37062658
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immuno-oncology drug and a tyrosine kinase inhibitor (TKI)
Study: 37062834
Drug: Metformin (open-label)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (open-label)
Study: 37062953
Drug: Triplet combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet combination of cabozantinib, nivolumab, and ipilimumab
Study: 37062953
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pembrolizumab plus lenvatinib plus belzutifan
Study: 37062953
Drug: Doublet combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet combination therapy with immune checkpoint inhibitors or immune checkpoint and tyrosine kinase inhibitor
Study: 37063238
Drug: Ad26.COV2.S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S vaccine (Janssen/Johnson & Johnson), single dose
Study: 37065899
Drug: CBD (Epidiolex®)
Normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD (Epidiolex®) 600 mg
Study: 37066198
Drug: Behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatments for RA
Study: 37066249
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg twice daily for four doses
Study: 37066828
Drug: VYC-15L treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VYC-15L treatment group
Study: 37067525
Drug: PARP inhibitors
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitors (PARPis)
Study: 37067525
Drug: Subsequent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent chemotherapy after PARPis
Study: 39652156
Drug: Mosunetuzumab monotherapy
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosunetuzumab monotherapy
Study: 37068273
Drug: Oral fluvoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluvoxamine (100 mg twice daily for 10 days) plus inhaled budesonide (800 mcg twice daily for 10 days)
Study: 37068889
Drug: Inhaled volatile
Normalized name: Peppermint volatile oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled volatile anaesthesia (INVA)
Study: 37068892
Drug: Repeated cervical
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated cervical ripening with prostaglandins (slow-release vaginal dinoprostone; oral misoprostol 25 µg; dinoprostone vaginal gel 2 mg)
Study: 37069359
Drug: Motixafortide and
Normalized name: Motixafortide
DrugBank: Motixafortide (DB14939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motixafortide and G-CSF
Study: 37069364
Drug: SEL-037 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEL-037 0.2 mg/kg + SEL-110 0.1-0.15 mg/kg
Study: 37069364
Drug: SEL-037 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEL-037 0.2 mg/kg alone
Study: 37069364
Drug: SEL-037 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEL-037 0.2 mg/kg + SEL-110 0.15 mg/kg
Study: 37069364
Drug: SEL-110 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEL-110 at doses up to 0.1 mg/kg
Study: 37069490
Drug: Standard Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Behavioral Treatment (ST)
Study: 37730530
Drug: Intradialytic exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic exercise (60 min during the second hour of thrice weekly dialysis for 6 months)
Study: 37069970
Drug: Ertugliflozin 5
Normalized name: ertugliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 5 mg or 15 mg (doses pooled for analyses)
Study: 37070436
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg once daily for 12 weeks)
Study: 37070473
Drug: Warfarin (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (vitamin K antagonist)
Study: 37070653
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor + CDK4/6 inhibitor
Study: 37070673
Drug: Living in
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living in extreme poverty (defined as below 120% of federal poverty thresholds) during ALL maintenance therapy.
Study: 37070673
Drug: Not living
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not living in extreme poverty (above 120% of federal poverty thresholds) during ALL maintenance therapy.
Study: 37071166
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (0.7 mL/kg iohexol 350 mgI/mL)
Study: 37071166
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1.4 mL/kg iohexol 350 mgI/mL)
Study: 37071469
Drug: L-ficolin, hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ficolin, hyaluronic acid (HA), and stimulation 2 (ST2) measured on day 3 after HCT
Study: 37071469
Drug: Low L-ficolin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low L-ficolin levels
Study: 37071469
Drug: L-ficolin levels
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ficolin levels
Study: 38722221
Drug: Avelumab first-line
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab first-line maintenance therapy
Study: 37072105
Drug: AZD4831 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831 5 mg
Study: 37072361
Drug: Risperidone (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (oral run-in)
Study: 37072603
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with gallium-aluminum-arsenide (GaAlAs) diode laser (810 nm, continuous-wave mode, 1000 mW, 0.28 cm)
Study: 37072607
Drug: Repository Corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository Corticotropin Injection (RCI, 80 U, subcutaneous, twice weekly for 24 weeks)
Study: 37072607
Drug: Repository Corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository Corticotropin Injection (RCI)
Study: 37072812
Drug: 15-week specialized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-week specialized low-intensity rehabilitation program, including exercise and respiratory therapy and mental gait training
Study: 37073421
Drug: Aspirin (prophylactic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (prophylactic, dosage not specified)
Study: 37073442
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine and bupivacaine (100 μg morphine and 15 mg bupivacaine)
Study: 37073794
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (discontinued anti-fibrotic therapy > 5 medication half-lives)
Study: 37073926
Drug: AneuFix elastomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: AneuFix elastomer injection into the endoleak cavity and lumbar arteries
Study: 37074202
Drug: mRNA-1283 vaccine
Normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1283 vaccine
Study: 37074571
Drug: Surufatinib 300
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 300 mg QD